Publications by authors named "B Soler"
Article Synopsis
- The study investigates the safety and effectiveness of ocrelizumab in Hispanic/Latino individuals with multiple sclerosis (MS), highlighting the need for real-world data from underrepresented populations in clinical trials.
- Out of 305 participants, the majority had relapsing-remitting MS, and the results showed minimal relapses and a significant reduction in MRI activity, with only 12.4% experiencing confirmed disability worsening.
- While the treatment was largely safe, with a low rate of serious infections and a consistent profile of outcomes, the study confirms ocrelizumab's effectiveness in this demographic at a specialized MS center.
Article Synopsis
- The study aimed to evaluate the reliability and validity of three questionnaires designed to assess dual-tasking difficulties in people with multiple sclerosis (PwMS).
- A total of 356 participants across six countries were analyzed, showing that the questionnaires had strong test-retest reliability and internal consistency, with the DIDA-Q performing the best.
- The findings indicate that these self-reported questionnaires are effective tools for measuring the impact of dual-task challenges on the daily lives of ambulatory PwMS in both research and clinical settings.
Introduction: Multiple Sclerosis (MS) is a chronic disease affecting around 2.8 million people worldwide. Two-thirds are women, and the mean age at diagnosis is about 30 years old.
View Article and Find Full Text PDFSocioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile.
Mult Scler Relat Disord
October 2023
Background: MS severity may be affected by genetic, patient-related, disease-related and environmental factors. Socioeconomic status, including income and healthcare access, amongst others, may also have a role in affecting diagnostic delay or therapy prescription. In Chile, two main healthcare systems exist, public-healthcare and private-healthcare, nonetheless universal care laws (e.
View Article and Find Full Text PDFBackground: Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease (MOGAD) is an emerging disorder recognized as a clinical entity distinct from Multiple Sclerosis and Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorders (NMOSD-AQP4+), and its phenotypic spectrum continues to expand. Most information about its clinical course has emerged from retrospective studies, and treatment response both in acute and chronic-relapsing disease is still limited. We aimed to describe the clinical and paraclinical characteristics of monophasic and relapsing, paediatric and adult patients with MOGAD under regular clinical care in Chile, highlighting some challenging cases that are far from being considered benign.
View Article and Find Full Text PDF